Chemical.AI
智化科技
Chemical.AI (智化科技) is a Wuhan-based AI pharmaceutical company founded in 2018 by Ning Xia, who holds a PhD in organic chemistry from the French Academy of Sciences and has spent over a decade working at the intersection of computing and chemical synthesis . The company specializes in AI-assisted chemical retrosynthesis, applying artificial intelligence to accelerate molecular design and synthesis planning in drug discovery .
In 2020, Chemical.AI was already being discussed alongside better-known peers like XtalPi and METiS Pharmaceuticals as part of the emerging AI drug discovery wave in China, and it secured multiple rounds of investment from prominent institutions that year . A notable early milestone came in January 2021, when French CRO firm NovAliX announced a strategic partnership with Chemical.AI to collaborate on AI for drug discovery . The company also contributed to pandemic response efforts in its home city during the early COVID-19 outbreak, helping coordinate medical supply needs for local hospitals .
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
峰瑞资本·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
峰瑞资本·Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
峰瑞资本·"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
峰瑞资本·FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
峰瑞资本·Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
峰瑞资本·How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
峰瑞资本·FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
峰瑞资本·New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
峰瑞资本·Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
峰瑞资本·FreeS Fund 2021 Outlook ② | Three Trends in Biomedical Innovation
The Biopharma Industry Enters the "Three Fast" Era
峰瑞资本·Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biomedical VC Summit Transcript
Why We're Bullish on AI Drug Discovery
峰瑞资本·Why Is AI Drug Discovery So Hot? And How Long Will It Stay Hot? | FreeS Fund Events & Research Recs
Three Slightly Brain-Burning Little Gifts
峰瑞资本·Supporting the Fight Against the Novel Coronavirus: Our Actions and Call to Action | FreeS Fund
Let's come together and help the people of Hubei get through this difficult time.
峰瑞资本·
